Theravance Biopharma, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for TBPH, updated each market day.
TBPH AI Sentiment
AI sees no strong directional signal for Theravance Biopharma, Inc. stock over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Theravance Biopharma, Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Sector
Exchange
Market Cap
$883,657,193
Cap Tier
Employees
90
Headquarters
GEORGE TOWN, GRAND CAYMAN, CA
Listed Since
May 16, 2014
Website
TBPH Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
TBPH Volatility
Theravance Biopharma, Inc. has shown low price volatility over the last 5 trading days. Low volatility suggests steady price action with smaller daily moves.
